公开(公告)号：US20210332143A1

公开(公告)日：2021-10-28

申请号：US17249530

申请日：2021-03-04

Applicant: Genentech, Inc.

Inventor： Mahrukh Huseni ,  Joanna E. Klementowicz ,  Yijin Li ,  Li-Fen Liu ,  Sanjeev Mariathasan ,  Mark Merchant ,  Luciana Molinero ,  Lifen Wang ,  Nathaniel West ,  Patrick Williams ,  Chi Yung Yuen ,  Edward Namserk Cha ,  Yulei Wang

IPC: C07K16/28 ,  A61P35/00 ,  A61K31/337 ,  A61K47/64

Abstract: This application discloses methods and compositions for use in treating cancer, including breast cancer (such as metastatic triple negative breast cancer, mTNBC), urothelial carcinoma, renal cell carcinoma, and liver cancer (hepatocellular carcinoma, HCC) with the combination of a PD-1 axis binding antagonist (e.g., a PD-L1 binding antibody such as atezolizumab) and an IL6 antagonist (e.g. an anti-IL6 receptor antibody such as tocilizumab), optionally further comprising a VEGF antagonist (e.g. an anti-VEGF antibody such as bevacizumab). Optionally, the patient has C-reactive protein (CRP) and/or IL-6 level(s) above the upper limit of normal. Optionally, the cancer is PD-L1 positive.